CiRC Biosciences Announces Orphan Drug Designation for Treatment of Retinitis Pigmentosa (RP)

CiRC Biosciences, Inc., a privately held cell therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for chemically induced photoreceptor-like cells (CiPCs) for the treatment of retinitis pigmentosa (RP). With an initial focus on retinal degenerative diseases, CiRC Biosciences is developing CiPCs as a potential therapy to treat RP, a genetic disorder affecting roughly 1 in 4,000 people. RP causes the breakdown of cells in the retina, impacting night and peripheral vision, often leading to blindness.

“The FDA’s orphan drug designation provides CiRC Biosciences with the opportunity to efficiently advance this technology through research and development stages to help make meaningful strides for this devastating disease,” said Sai Chavala M.D., co-founder and chief scientific officer of CiRC Biosciences. “We are excited about the work ahead of us as we explore and advance cell therapies, with the ultimate goal of restoring vision to those impacted by retinitis pigmentosa and potentially other retinal diseases. Today’s announcement serves as an acknowledgement of the team’s work to advance our novel transdifferentiation platform and our lead investigational candidate—chemically induced photoreceptor-like cells.”

CiRC Biosciences is currently advancing pre-clinical development of CiPCs for vision restoration in advanced RP and geographic atrophy age-related macular degeneration. The company’s novel technology enables direct chemical transdifferentiation of fibroblasts into other cell types using a cocktail of small molecules in a chemical conversion process that takes less than two weeks. A study conducted in a mouse model of RP showed that CiPCs lead to partial restoration of the pupil reflex and visual function. Results were published in the journal Nature in 2020. 

RP symptoms typically appear in early adulthood or childhood. Individuals with RP commonly have issues maneuvering in the dark and take unusually long periods of time adjusting to lighting changes. As the disease progresses, people with RP can experience clumsiness due to restrictions in their field of vision. The severity and progression of vision loss depends on the type of gene mutation inherited. Currently there are no FDA-approved treatments to restore vision loss for patients with RP.

To Read the Complete Article at PR Newswire, Click Here

Disclaimer: BioPharma Global is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use, reference to, or reliance on any information contained within the article. Content available through the site may contain links and information to other websites. Links from BioPharma Global to third-party sites do not constitute an endorsement by BioPharma Global of the mentioned parties.

BioPharma Global is a mission-driven corporation, operating like a not-for-profit, dedicated to using our FDA and EMA regulatory expertise and knowledge of various therapeutic areas to help drug developers advance treatments for the disease communities with a high unmet medical need. If you are a drug developer seeking regulatory support for Orphan Drug designation, Fast Track designation, Breakthrough Therapy designation, other FDA/EMA expedited programs, type A, B (pre-IND, EOPs), or C meeting assistance, or IND filings, the BioPharma Global team can help. Contact us today to arrange a 30-minute introductory call.

Stock image by @everythingposs from Depositphotos